Reports Q1 revenue $7.543M, consensus $9.66M. “Codexis (CDXS) finished the first quarter with $60 million in cash, which remains on track to fund the company through cash flow positivity by the end of 2026,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “Importantly, the Q1 revenue guidance we outlined in February included a $2.5 million one-time payment from a Pharma Biocatalysis customer due in March which was received in April. Since this has no impact on our overall 2025 revenue projections, we are confident in reiterating our 2025 guidance and the current range of published analyst estimates.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDXS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue